This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

HomeBrowseAboutFAQs
Log In
Sign Up
Raynaud's Disease

Dose Response Study of a Topical Formulation of Nitroglycerin for the Treatment of Raynaud's Phenomenon

Sponsored by MediQuest Therapeutics

About this trial

Last updated 17 years ago

Study ID

07-003

Status

Completed

Type

Interventional

Phase

Phase 2

Placebo

No

Accepting

18-75 Years
18 to 75 Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Ended 18 years ago

What is this trial about?

The purpose of this clinical study is to determine the response to two different dosage strengths of a topical nitroglycerin gel in patients with Raynaud's Phenomenon. Patient fingers will be monitored for changes in blood flow and skin temperature. Symptoms of pain, tingling and numbness will also be monitored.

What are the participation requirements?

Yes

Inclusion Criteria

- Patients with Raynaud's phenomenon

- Patients who are willing to discontinue any current therapies for Raynaud's phenomenon

No

Exclusion Criteria

- The use of any medication containing nitroglycerin or known to interact with nitroglycerin

- Patients with a history of migraine or other severe headaches

- Open skin lesions or skin conditions in the area where medication is to be applied

- Pregnant or nursing women or those wishing to become pregnant.